Your browser doesn't support javascript.
loading
Case report: Joint deformity associated with systemic lupus erythematosus.
Chen, Shu-Lin; Zheng, Hui-Juan; Zhang, Li-Yu; Xu, Qiang; Lin, Chang-Song.
Affiliation
  • Chen SL; Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Zheng HJ; The First Clinical Medicine School, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Zhang LY; Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Xu Q; The First Clinical Medicine School, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Lin CS; Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Immun Inflamm Dis ; 10(10): e717, 2022 10.
Article in En | MEDLINE | ID: mdl-36169251
ABSTRACT

OBJECTIVE:

Typically, Jaccoud arthropathy (JA) is characterized by joint deformation without bone erosion. However, some recent studies have shown that bone erosion also occurs in JA; however, this remains controversial. To date, there have been no unified diagnostic standards for JA. Herein, we report a case of systemic lupus erythematosus complicated with JA without bone erosion.

METHODS:

A 27-year-old woman was admitted to our department with a 2-year history of pain, swelling, and progressive deformities of her hands and feet. She was diagnosed with systemic lupus erythematosus and class V lupus nephritis 5 years prior. Upon examination, her erythrocyte sedimentation rate and C-reactive protein levels were found to be increased. She was positive for antinuclear antibodies, antidouble stranded DNA antibodies, and antiextractable nuclear antigen antibodies, with a decreased complement C3 and C4. Radiography and magnetic resonance imaging revealed no bone erosion. The patient was diagnosed with JA. She was treated with oral prednisone (10 mg daily), tofacitinib (5 mg twice daily), methotrexate (10 mg weekly), and celecoxib (0.2 g twice daily).

RESULTS:

The patient's joint symptoms improved after treatment. No further progress was observed during the 4-month follow-up period.

CONCLUSION:

We believe that bone erosion is the key to distinguish rhupus syndrome from JA. However, this needs to be confirmed with further long-term follow-up studies. We found that the use tofacitinib, MTX, and celecoxib in combination with prednisone may be an effective regimen for the treatment of JA.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Lupus Erythematosus, Systemic Type of study: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans Language: En Journal: Immun Inflamm Dis Year: 2022 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Lupus Erythematosus, Systemic Type of study: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans Language: En Journal: Immun Inflamm Dis Year: 2022 Document type: Article Affiliation country: China